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Percutaneous coronary intervention (PCI) with stent placement is a standard treatment for coronary artery disease (CAD). In-
stent restenosis after PCI remains a challenging clinical problem. In China, Chinese herbal medicines (CHMs) are widely used
for preventing restenosis. This paper systematically reviewed the literature on the eﬀectiveness and safety of CHMs in preventing
restenosis after PCI in patients with CAD. Electronic databases were searched for randomized controlled trials that compared
CHMs plus RWM with the same RWM plus placebo in preventing restenosis after PCI. A total of 52 trials (4905 patients) on 34
CHMs met the inclusion criteria and were analyzed. Ten trials had low risk of bias. Methodological quality of included trials was
generally poor. Meta-analysis showed that at the end of at least 3 months’ followup, CHMs plus RWM could signiﬁcantly reduce
restenosis rate, cardiac mortality, recurrence rate of angina, acute myocardial infarction, numbers of repeat PCI, and numbers
of coronary artery bypass graft. Reported adverse events included gastrointestinal upset, granulocytopenia, and increased alanine
transaminase (ALT). CHMs may help prevent restenosis, thus reducing cardiac mortality after PCI. Caution should be exercised
in drawing a deﬁnitive conclusion due to the poor methodological quality of the trials reviewed.
1.Introduction
Coronary artery disease (CAD) is the single leading cause
of death and disability in the world [1–3]. Percutaneous
coronaryintervention(PCI)withstentplacementisthestan-
dardnonsurgicaltreatmentforCAD,eﬀectiveinrelievingthe
symptoms of coronary ischemia [4]. But the main limitation
of coronary stenting, in particular with bare-metal stents, is
in-stent restenosis (ISR) [5]. This is the formation of scar
tissue over the stent, which can cause the opened artery to
narrowagain.TherisksofISRincludesymptomsofcoronary
ischemia,oftenwarrantingrepeatrevascularization[6].With
the development and the universal application of the drug-
elutingstent(DES),restenosishasbeenreducedfrom10%to
5 0 %f o rb a r e - m e t a ls t e n t s[ 7]t o<10% for DESs [8]. Despite
this improvement, a major drawback of DESs has come to
light involving late (after 30 days) and very late (after 1 year)
stent thrombosis [9, 10]. In addition, studies have shown
that DESs do not reduce late cardiac-related death and the
incidenceofmyocardialinfarction(MI)[11–14].Antithrom-
botic therapy after PCI, consisting of lifelong aspirin and
clopidogrel, is eﬀective in reducing cardiac-related death,
MI, and stroke [15]. But dual antiplatelet therapy also has
limitations, as stopping prematurely signiﬁcantly increases
the risk of stent thrombosis, MI, and death [16]. Thus,
treatment of ISR remains a challenging clinical issue.
In China, Chinese herbal medicines CHMs have a long
historyofintegrationwithroutineWesternmedical(conven-
tional) interventions. Advancements in such interventions
have spurred concomitant application of CHMs in attempts
to enhance outcomes. In the past decade, CHMs have been
tested in clinical trials as an adjunct therapy for preventing2 Evidence-Based Complementary and Alternative Medicine
ISR after PCI. CHMs appear to ameliorate ISR after PCI
whenusedaloneorcombinedwithroutinewesternmedicine
(RWM) [16, 17]. Pharmacologic studies have found that
some (CHMs) can be administered to dilate coronary
vessels, improve circulation, and remove blood stasis (Chi-
nese medicine concept of blood circulation disturbance,
resulting in slowing of blood ﬂow, thrombosis, retained
blood). Additionally, these CHMs possess antiinﬂammatory,
immune response inhibition, anti-platelet aggregation, and
antiperoxidative properties, as well as functions that inhibit
proliferation and migration of vascular smooth muscle cells
[18–21]. Reviews on the eﬃcacy of CHMs in preventing
restenosis after PCI have been published in Chinese [22–24].
But the evidence supporting or disproving the beneﬁts of
CHMs is not robust because of methodological deﬁciencies
of those reviews. Our study presents a more vigorous
attempt to examine the existing studies to draw more
useful conclusions about the safety and eﬃcacy of CHMs in
preventing restenosis post-PCI.
2. Methods
2.1. Inclusion Criteria. Only randomized controlled trials
(RCTs) were included regardless of being published or
unpublished. We focused on trials with participants diag-
nosed with major angiographic criteria-documented [25]
coronary artery disease who were eligible for PCI regardless
of gender, age, and ethnic origin.
The treatment group in the trials was treated with any
CHM, or CHM plus RWM with at least 1 month of therapy
regardless of dosage. The control group was treated with
the same RWM based on the Chinese Society of Cardiology
guidelines for percutaneous transluminal coronary interven-
tion [25], or the same RWM plus placebo. “Chinese herbal
medicines” include extracts from mixtures of herbs, single
herbs, Chinese prepared medicines, or a compound of herbs
that is prescribed by a Chinese medicine practitioner [26].
Primary outcome measures were restenosis, cardiac
death, and adverse events occurring in at least 3 months of
followup. Secondary outcome measures included recurrent
angina, acute myocardial infarction (AMI), revasculariza-
tion, repeat PCI, coronary artery bypass graft (CABG),
minimal luminal diameter (MLD), late loss of lumen (LLL),
net gain in lumen diameter (NG), and lesion area net gain
(LANG) after PCI, and quality of life during at least 1 month
of followup.
2.2. Study Identiﬁcation and Assessment in Included Studies.
Two authors (G.-H.Zheng, H.-Y.Chen) independently iden-
tiﬁedstudiesthroughsearchesoftheCochraneLibrary(Issue
4, 2010), PubMed (January1966 to December 2010), Embase
(January 1980 to December 2010), the China Biological
Medicine Database (CBM, January 1980 to December 2010),
Chinese Scientiﬁc Journal Database (VIP, January1989 to
December 2010), China National Knowledge Information
database (CNKI, January 1994 to December 2010) and
Chinese Medical Citation Index (CMCI, January 1999 to
December 2010) with free terms related to heart disease
and CHM (e.g., “coronary heart disease” OR “coronary
artery disease” OR “cardiovascular disease” OR “percuta-
neous coronary intervention” OR “stent” OR “stenosis”
OR “restenosis” OR “CHD” OR “CVD” OR “CAD” OR
“MI” “Chinese” OR “herbal” OR for English databases. The
Chinese counterpart terms were used for Chinese databases.
The reference list of each relevant article was searched for
further studies. Unpublished literature was searched using
Chinese Master’s Theses Full-text Database (CMFD), China
Doctor Dissertation Full-text Database (CDFD) and China
Proceedings of Conference Full-text Database (CPCD).
Risk of bias in included studies was assessed using The
Cochrane Collaboration’s tool for assessing risk of bias.
Six criteria were applied: adequate sequence generation,
concealment of allocation, blinded of primary outcomes,
adequately addressed incomplete outcome data, free from
selective reporting, and free of other risk of bias [27]. In
addition, we assessed the baseline characteristics between the
comparison groups.
2.3. Data Extraction. Two authors (G.-H. Zheng, J.-F. Chu)
independently selected those trials that met the inclusion
criteria and extracted details on randomization, allocation
concealment, blinding, intent to treat analysis, numbers lost
to followup, patient demographics, methods, interventions,
outcomes, and results. Missing data were obtained from the
original authors when possible.
2.4. Data Analysis. Heterogeneity across studies was tested
using a standard χ2 test [28] and Higgins I2 [29]. When
heterogeneity was not signiﬁcant (P ≥ 0.1), the results
were pooled using a ﬁxed eﬀect model and the Mantel-
Haenszel test. Otherwise, a random eﬀect model and the
Dersimonian and Laird method were applied [30]. The
results were reported as risk ratio (RR) with corresponding
95% conﬁdence interval (CI) for dichotomous data. If
continuous data were available, weighted mean diﬀerence or
standardized mean diﬀerence was calculated [31]. All data
were analyzed using the statistical software RevMan 5.0.1
(Oxford, England) of The Cochrane Collaboration, and all
P values were two sided.
3. Results
3.1. Study Identiﬁcation. Eligible literature was screened and
identiﬁed (Figure 1). A total of 806 records were retrieved.
Of these, full-text evaluation was conducted on 154 studies.
This was followed by elimination of 102 studies: irrelevant
to CHM (n = 61); irrelevant to the primary or secondary
outcomes (n = 10); control group combined with another
CHM (n = 23); duplicate publication (n = 6) [32–37];
primary outcomes <3 months’ followup (n = 1)[38]; CHM
treatment <1 month treatment (n = 1) [39]. Finally, 52
RCTs with a total of 4905 patients in treatment and control
groups, fulﬁlled the inclusion criteria [40–91]. All studies
were conducted in China from 1979 to 2010.
3.2. Characteristicsof Included RCTs. Table 1 summarizes the
characteristics of included studies. Average age of patients
in the included studies ranged from 51.2 to 72 years. EachEvidence-Based Complementary and Alternative Medicine 3
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CBM
n = 106
CMCI
n = 116
CNKI
n = 422
VIP
n = 110
Unpublished: CMFD,
CDFD, CPCD, n = 22
PubMed, Embase,
Cochrane Library, n = 30
Potentially relevant
articles, n = 522
Possible relevant
articles, n = 131
Possible eligible
articles, n = 60
Eligible articles with usable
information fulﬁlling all
inclusion criteria, n = 52
Full-text articles for
more detailed
evaluation, n = 154
284 articles excluded because of overlap, according to title and author 
names
23 articles identiﬁed from scanning references of relevant narrative
94 full-text articles excluded: irrelevant to Chinese herbal medicine,
n = 61; irrelevant to primary or secondary outcomes,
8 articles excluded: duplicate publication, n = 6; primary
outcome follow-up period < 3 months, n = 1; CHM treatment
period < 1 month, n = 1
391 articles excluded by reading their abstracts:
irrelevant to CAD or PCI, n = 121; narrative reviews, n = 37; cardiac
rehabilitation, n = 18; animal experiments, n = 56; molecular biology
experiments, n = 62; drug’-eluting stent studies, n = 97
reviews
n = 10; not comparing same CHMs, n = 23
Figure 1: Literature search and selection. Abbreviations: CBM: China Biological Medicine Database; CDFD: China Doctor Dissertation
Full-Text Database; CMCI: Chinese Medical Citation Index; CMFD: Chinese Master’s Theses Full-Text Databases; CNKI: China National
Knowledge Infrastructure; CPCD: China Proceedings of Conference Full-text Database; VIP: VIP Database.
trial had more males than females. The diagnostic criteria of
CAD were mainly based on coronary angiography criteria.
All patients successfully underwent PCI.
Four trials [45, 67, 71, 81]w e r er a n d o m i z e dd o u b l e
blind, and placebo controlled comparing RWM plus CHM
versus the same RWM plus placebo. The remaining trials
were designed comparing CHM plus RWM versus the same
RWM alone. The dosage and types of RWM were prescribed
according to Chinese Society of Cardiology guideline rec-
ommendations [25]. In the trials, 34 kinds of CHMs were
used, and the period of treatment with a CHM was at least
1 month. Followup after PCI ranged from 3 to 12 months,
with 6 months in the majority of studies.
Restenosis was assessed using angiography in 40 trials.
Of these, 10 studies reported angiography assessments at the
end of at least 3 months after PCI. Adverse events caused by
CHMs were reported in 21 studies, but none of the studies
underwentstatisticalanalysis.Recurrentanginawasreported
in 33 studies. Major cardiac events were reported in 16 trials,
and 10 trials reported cardiac death after followup of at least
6 months. Only 2 studies assessed quality of life using the
Short-Form 36 (SF-36) Health Survey and Seattle Angina
Questionnaire (SAQ) at the end of 1 month after PCI.
Adequate sequence generation?
Allocation concealment?
Blinding?
Incomplete outcome data addressed?
Free of selective reporting?
Free of other bias?
0 25 50 75 100
Yes (low risk of bias)
Unclear
No (high risk of bias)
(%)
Figure 2: Risk of bias graph depicting proportions of studies with
each judgment.
3.3. Methodological Quality of Included RCTs. Risk of bias
in the studies is shown in Figure 2. Of the 52 studies,
19 studies reported randomization using random number
tables or computer random number generator such as SAS.
The remaining 33 studies reported “randomly allocating”
participants, but the method of randomization was notEvidence-Based Complementary and Alternative Medicine 9
Table 2: Risk ratios of Chinese herbal medicines administered to prevent restenosis after PCI.
Chinese herbal medicine Number of studies Number of patients Risk ratio (RR) 95% CI of RR
Bu xin yin plus RWM versus RWM 1 [76] 44 0.69 0.23∼2.01
Chuan qiong qing plus RWM versus RWM 1 [65] 165 0.51 0.19∼1.31
Dan hong tong mai capsule plus RWM versus RWM 1 [91] 103 0.35 0.10∼1.23
Dan shen plus RWM versus RWM 5 [44, 50, 52, 85, 86] 388 0.27 0.14∼0.52
Ge gen shu plus RWM versus RWM 1 [42] 76 0.23 0.06∼0.95
Guan mai zhai tong decoction plus RWM versus RWM 1 [68] 92 0.32 0.09∼1.11
Guan tong formula plus RWM versus RWM 1 [54] 120 0.43 0.18∼1.04
Jia wei xue fu zhu yu particle plus RWM versus RWM 1 [51] 40 0.75 0.27∼2.07
Jiang lian he ji plus RWM versus RWM 1 [63] 26 0.57 0.11∼2.87
Ku lie zhi injection plus RWM versus RWM 1 [78] 40 1.00 0.07∼14.9
Lei gong teng plus RWM versus RWM 2 [43, 64] 133 0.75 0.40∼1.40
Liang xue shen ji formula plus RWM versus RWM 1 [46] 97 0.45 0.12∼1.70
Shen qi decoction plus RWM versus RWM 1 [89] 68 0.47 0.09∼2.40
S h ux i ny i np l u sR W Mversus RWM 1 [75] 44 0.69 0.23∼2.01
Si ni tang plus RWM versus RWM 1 [59] 63 0.55 0.14∼2.09
Tong guan capsule plus RWM versus RWM 1 [70] 25 0.67 0.26∼1.72
Tong mai yu xin plus RWM versus RWM 2 [60, 62] 272 0.39 0.21∼0.70
Tong xin fang plus RWM versus RWM 1 [49] 61 1.03 0.23∼4.72
Tong xin luo plus RWM versus RWM 4 [39, 79, 82, 90] 328 0.34 0.20∼0.59
Wen tong jian plus RWM versus RWM 1 [87] 467 0.03 0.00∼0.49
Xue fu zhu yu pin plus RWM versus RWM 2 [72, 84] 157 0.61 0.32∼1.16
Xue yu tong he ji plus RWM versus RWM 1 [69] 36 1.0 0.16∼6.35
Xue zhi kang plus RWM versus RWM 1 [48] 55 0.30 0.09∼0.99
Xing mai fu tong decoction plus RWM versus RWM 1 [61] 70 0.71 0.17∼2.94
Xiong shao capsule plus RWM versus RWM 2 [40, 80] 173 0.43 0.23∼0.81
Yi qi hua yu formula plus RWM versus RWM 1 [41] 100 0.13 0.02∼1.10
Yi xin capsule plus RWM versus RWM 1 [77] 94 0.50 0.27∼0.91
Self-prepared guantong decoction plus RWM versus RWM 1 [83] 30 0.40 0.16∼1.00
Overall (CHMs plus RWM versus RWM) 38 3367 0.43 0.36∼0.51
Xiong shao capsule plus RWM versus R W Mp l u sp l a c e b o 2[ 67, 81] 438 0.46 0.27∼0.76
Overall (CHMs plus RWM versus RWM plus placebo) 2 438 0.46 0.27∼0.76
CHM = Chinese herbal medicine; CI = conﬁdence interval; RWM = routine Western medicine.
described. Allocation concealment in 10 of the 52 studies
was by sealed, opaque envelopes. In 9 trials, participants
and/or outcome assessors were blinded. In most studies, data
collection was clearly described and reported, so we judged
them as free of selective reporting outcomes. We graded
28 of the 52 studies as “unclear” in terms of free of other
bias because there was no evidence of statistical testing of
baseline characteristics between comparison groups or the
outcome data were incomplete. As a whole, 10 studies [44–
46, 53, 67, 71, 75, 76, 81, 85] had low risk of bias with high
methodological quality. Most studies were found to be high
risk of bias with low methodological quality.
3.4. Measures of Eﬀect
3.4.1. Restenosis. In 40 studies on 29 Chinese herbal med-
icines (CHMs) comprised of 3805 patients, restenosis was
assessed using coronary angiography after PCI with at least
3 months’ followup (Table 2). Compared to RWM alone, the
rate of restenosis was clearly low in patients administered the
same RWM plus CHMs. Of 29 CHMs, 9 CHMs (including
Xiong shao capsule, Dan shen, Ge gen shu, Tong mai yu xin
pill, Tong xin luo, Wen tong jian, Xue zhi kang, Yi xin capsule,
and self-prepared guan tong decoction) showed signiﬁcant
ability in reducing restenosis. In particular, two studies
[67, 81]o nXiongshao capsule (438 patients) appeared to
have reliable results because their designs were randomized,
double blinded, and placebo controlled. The overall risk
ratio (RR) of restenosis was 0.46 with 95%CI = 0.27 to 0.76
compared to placebo.
3.4.2. Cardiac Mortality. In 10 studies on 9 CHMs, com-
prised of 628 patients in the treatment group and 667
patients in the control group, cardiac death was included
as a measure of eﬀect at the end of 6 months of follow-up
after PCI. A pooled analysis of CHM plus RWM versus the
same RWM found a statistically signiﬁcant decrease in risk
of cardiac death associated with CHM, though we did not10 Evidence-Based Complementary and Alternative Medicine
Table 3: Risk ratios of Chinese herbal medicines administered to prevent cardiac mortality after PCI.
Chinese herbal medicine Number of studies Number of patients Risk ratio (RR) 95% CI of RR
Bu xin yin plus RWM versus RWM 1 [76] 44 0.4 0.02∼9.24
Chuan qiong qing plus RWM versus RWM 1 [65] 165 0.23 0.01∼4.38
Dan hong tong mai capsule plus RWM versus RWM 1 [91] 138 2.92 0.12∼70.35
Dan shen plus RWM versus RWM 2 [44, 85] 168 0.33 0.03∼3.07
Ku lie zhi injection plus RWM versus RWM 1 [78] 40 0.33 0.01∼7.72
Liang xue shen ji formula plus RWM versus RWM 1 [46] 97 0.15 0.02∼1.2
S h ux i ny i np l u sR W Mversus RWM 1 [75] 44 0.40 0.02∼9.24
Tong xin luo plus RWM versus RWM 1 [79] 132 0.38 0.02∼9.06
Wen tong jian plus RWM versus RWM 1 [87] 467 0.07 0.00∼1.32
Overall (CHMs plus RWM versus RWM) 10 1295 0.27 0.11∼0.63
CHM = Chinese herbal medicine; CI = conﬁdence interval; RWM = routine Western medicine.
ﬁnd a signiﬁcant diﬀerence upon subgroup analysis based on
diﬀerent CHMs (Table 3).
3.4.3. Adverse Eﬀects. Adverse eﬀects due to CHMs were
not mentioned in 30 studies. In 14 studies, the authors
reported that there were no noteworthy adverse events.
The remaining 8 studies on 7 CHMs reported adverse
events, including gastrointestinal upset, granulocytopenia,
elevated alanine transaminase (ALT), aphthous stomatitis,
skinpruritus,papularurticaria.Mostadverseeventswerenot
severe and disappeared without special treatment. With the
CHM Lei gong teng, adverse events in the treatment group
were higher than those in the control group (RR = 37.02,
95%CI = 2.29 to 597.88). With CHM Si ni tang, adverse
events in the treatment group were lower than that of the
control group (RR = 0.38, 95%CI = 0.21 to 0.69). There was
no statistically signiﬁcant diﬀerence between the two groups
in the remaining 5 CHMs. Pooled analysis could not be done
in 8 studies on 7 CHMs because of heterogeneity among the
studies.
3.4.4. Recurrent Angina. Recurrent angina 6 months post-
PCI was reported as a measure of eﬀect in 33 studies
comprised of 3375 patients (Table 4). The rate of recurrent
angina in the RWM plus CHM group was lower than that
of the same RWM alone group for the CHMs Dan hong tong
maicapsule,Danshen,Guantongformula,Leigongteng,Tong
maiyixinpill,Tongxinluo,Wentongjian,Xiongshaocapsule,
Xue fu zhu yu pill, Xue zhi kang, Wen yang huo xue formula.
Astatisticallysigniﬁcantdiﬀerencewasnotobservedforeach
of the remaining CHMs. Pooled results of these trials showed
recurrent angina was signiﬁcantly decreased. For Xiong shao
capsule, risk of recurrent angina was clearly decreased in the
CHM plus RWM group than in the same RWM plus placebo
control group.
3.4.5. Major Adverse Cardiac Eﬀects
Acute Myocardial Infarction (AMI). In 15 studies on 9
CHMs, involving 1551 patients, acute myocardial infarction
w a sr e p o r t e da sam e a s u r eo fe ﬀect 6 months after PCI
(Table 5). No statistically signiﬁcant diﬀerence was found in
each study, but meta-analysis did show decreasing incidence
of AMI in the CHM plus RWM group (RR = 0.22, 95%CI =
0.1 to 0.49).
Revascularization. Revascularization after the index PCI was
reported as a measure of eﬀect in 6 studies on 4 CHMs
(Shu xin yin, Bu xin yin, Yi xin capsule, and Xiong shao
capsule) comprised of 716 patients (Table 5). Numbers of
revascularization in the CHM plus RWM group was not
signiﬁcantly lower than that in RWM alone group (RR =
0.64, 95% CI = 0.38 to 1.08). However, compared to RWM
plusplacebo,administeringCHMXiongshaocapsuleplusthe
same RWM (2 studies with 426 patients) clearly reduced the
numbers of revascularization (RR = 0.48, 95%CI = 0.30 to
0.78).
Repeat PCI. Repeat PCI was reported as a measure of eﬀect
in 9 studies, which involved 8 CHMs with 807 patients
(Table 5). Numbers of repeat PCI in the CHM plus RWM
group was lower than that of the RWM alone group for Fu
fangdanshenpill (RR =0.14,95%CI =0.03to0.58)andTong
xin luo (RR = 0.16, 95%CI = 0.04 to 0.68). The remaining
CHMs showed no statistically signiﬁcant diﬀerence between
the CHM plus RWM group and RWM alone group. But
the overall result of their meta-analyses showed an obvious
statistical diﬀerence between CHMs plus RWM versus RWM
groups (RR = 0.37, 95%CI = 0.23 to 0.59).
Coronary Artery Bypass Graft. Coronary artery bypass graft
(CABG) after index PCI was reported as a measure in 9
studies on 7 CHMs with 1141 patients (Table 5). CHM plus
RWM was found to markedly reduce the risk of CABG over
the same RWM alone (RR = 0.29, 95%CI = 0.09 to 0.96). But
compared to RWM plus placebo, CHM Xiong shao capsule
plusRWMcouldnotreduceriskofCABG(RR=0.20,95%CI
= 0.02 to 1.68).
3.4.6. Eﬀect on Angina. Eﬀect on angina was reported as
a measure in 6 studies with 522 patients (Table 6). Two
studies reported a followup period of 1 month, 2 studies
reported a followup of 3 months, and 2 studies reported
afollowupof6monthsafterindexPCI.AnginaimprovementEvidence-Based Complementary and Alternative Medicine 11
Table 4: Risk ratios of Chinese herbal medicines administered to prevent recurrent angina after PCI.
Chinese herbal medicine Number of studies Number of patients Risk ratio (RR) 95% CI of RR
Bu xin yin plus RWM versus RWM 1 [76] 44 0.60 0.33∼1.10
Dan hong tong mai capsule plus RWM versus RWM 1 [91] 138 0.24 0.07∼0.82
Dan shen plus RWM versus RWM 5 [44, 50, 57, 85, 86] 390 0.24 0.15∼0.41
Guan tong formula plus RWM versus RWM 1 [54] 120 0.27 0.08∼0.93
Jia wei xue fu zhu yu particle plus RWM versus RWM 1 [51] 60 0.45 0.18∼1.15
Jiang lian he ji plus RWM versus RWM 1 [63] 69 0.71 0.30∼1.70
Lei gong teng plus RWM versus RWM 1 [64] 75 0.39 0.17∼0.94
Liang xue shen ji formula plus RWM versus RWM 1 [46] 97 0.52 0.16∼1.65
Shu xue tong injection plus RWM versus RWM 1 [56] 43 0.37 0.11∼1.25
S h ux i ny i np l u sR W Mversus RWM 1 [75] 44 0.60 0.33∼1.10
Tong guan capsule plus RWM versus RWM 1 [70] 50 0.67 0.22∼2.01
Tong mai yi xin plus RWM versus RWM 2 [54] 272 0.41 0.26∼0.65
Tong xin luo plus RWM versus RWM 3 [79, 82, 90] 344 0.27 0.13∼0.54
Wen tong jian plus RWM versus RWM 1 [87] 467 0.30 0.17∼0.52
Wen yang huo xue formula plus RWM versus RWM 1 [47] 120 0.53 0.38∼0.75
Xue fu zhu yu pin plus RWM versus RWM 2 [72, 84] 157 0.44 0.25∼0.78
Xue yu tong he ji plus RWM versus RWM 1 [69] 36 0.67 0.23∼1.97
Xue zhi kang plus RWM versus RWM 1 [48] 60 0.38 0.16∼0.94
Xiong shao capsule plus RWM versus RWM 2 [40, 80] 173 0.48 0.31∼0.75
Yi qi hua yu formula plus RWM versus RWM 1 [41] 60 0.44 0.15∼1.29
Yi xin capsule plus RWM versus RWM 1 [77] 94 0.46 0.20∼1.05
Self-prepared guan tong decoction plus RWM versus RWM 1 [83] 40 0.33 0.11∼1.05
Overall (CHM plus RWM versus RWM) 31 2953 0.40 0.35∼0.47
Xiong shao capsule plus RWM versus R W Mp l u sp l a c e b o 2[ 67, 81] 422 0.25 0.17∼0.37
CHM plus RWM versus RWM plus placebo 2 422 0.25 0.17∼0.37
CHM = Chinese herbal medicine; CI = conﬁdence interval; RWM = routine Western medicine.
in these studies was deﬁned as “signiﬁcant improvement,”
“improvement,” and “no improvement” based on Chinese
herbal medicine clinical research guidelines [92]. To permit
overall analysis, we converted these outcomes into dichoto-
mous data. We grouped together “signiﬁcant improvement”
and “improvement” as “eﬀective,” and “no improvement” as
“ineﬀective.” There was no statistically signiﬁcant diﬀerence
between CHM plus RWM versus RWM groups for every
CHM except for Shen mai gua lou shi xiao powder (RR =
1.55, 95%CI = 1.11 to 2.17). Furthermore, the results were
unsuitableformeta-analysispoolingduetoheterogeneity(I2
= 60%).
3.4.7. Angiographic Measurements. Follow-up angiography
was done on diﬀuse ISR 6 months after index PCI in 10 stud-
ieson8CHMswith811patients.Baselineinformationshows
that the mean minimal luminal diameter (MLD) before and
immediately after index PCI and gain in luminal diameter
following stent placement were comparable between the
comparison groups.
MinimumLumenDiameter(MLD). Minimum lumendiam-
eter is deﬁned as smallest diameter of the lesion area being
treated[93].MLDwasmeasuredin7CHMstudies(Table 7).
The CHM plus RWM groups showed signiﬁcant MLD
improvement over the same RWM alone or plus placebo for
Fu fang dan shen capsule (MD (mean diﬀerence) = 0.05mm,
95%CI = 0.04 to 0.26mm), Guan tong formula (MD =
0.21mm, 95%CI = 0.06 to 0.36mm) and Xiong shao capsule
(placebocontrol;MD=0.49mm,95%CI=0.12to0.86mm).
No signiﬁcant diﬀerence was evident in the studies on Lei
gong teng, Tong xin fang, Si ni tang. But in pooling the results
of those trials, there was a statistically signiﬁcant diﬀerence
(MD = 0.15mm, 95%CI = 0.05 to 0.24mm), with patients
receiving CHMs more likely to have increased MLD than
those in the control group.
Late Loss of Lumen (LLL). Late loss of lumen is deﬁned as
the decreased amount in lumen diameter after PCI, which
is calculated by subtracting MLD at followup from MLD
immediately post-procedure [93]. LLL was measured in 6
studies on 5 CHMs after 6 months’ followup (Table 7). Five
studieson4CHMs(Guantongformula,Tongxinluo,Shuxue
tong injection, and Lei gong teng) reported signiﬁcantly better
results for reducing late loss of lumen in the treatment group
over the control group. There was no signiﬁcant diﬀerence
in the study on Fu fang dan shen capsule. The pooled results
showed signiﬁcant diﬀerence (MD = −0.24mm, 95%CI =
−0.34 to −0.15mm).
N e tG a i ni nL u m e nD i a m e t e r( N G ) .Net gain in lumen
diameterisdeﬁnedasthenetincreaseinMLDafterPCI[93].12 Evidence-Based Complementary and Alternative Medicine
Table 5: Risk ratios of Chinese herbal medicines administered to prevent MACE after PCI.
Chinese herbal medicine Number of studies Number of patients Risk ratio (RR) 95% CI of RR
Acute myocardial infarction
Bu xin yin plus RWM versus RWM 1 [76] 44 0.24 0.01∼4.69
Dan hong tong mai capsule plus RWM versus RWM 1 [91] 138 0.14 0.01∼2.64
Dan shen plus RWM versus RWM 2 [44, 85] 168 0.14 0.02∼1.11
Fu fang dan shen pill plus RWM versus RWM 2 [50, 57] 156 0.32 0.03∼2.99
Ku lie zi injection plus RWM versus RWM 1 [78] 40 0.33 0.01∼7.72
S h ux i ny i np l u sR W Mversus RWM 1 [75] 44 0.24 0.01∼4.69
Tong xin luo plus RWM versus RWM 2 [79, 90] 268 0.25 0.03∼2.22
Xiong shao capsule plus RWM versus RWM 2 [40, 80] 173 0.14 0.02∼1.06
Yi xin capsule plus RWM versus RWM 1 [77] 94 0.65 0.06∼6.88
Overall (CHMs plus RWM versus RWM) 13 1125 0.22 0.10∼0.49
Xiong shao capsule plus RWM versus R W Mp l u sp l a c e b o 2[ 73] 426 0.59 0.08∼4.41
Overall (CHMs plus RWM versus RWM plus placebo) 2 426 0.59 0.08∼4.41
Revascularization
S h ux i ny i np l u sR W Mversus RWM 1 [75] 44 0.69 0.23∼2.01
Bu xin yin plus RWM versus RWM 1 [76] 44 0.69 0.23∼2.01
Yi xin capsule plus RWM versus RWM 1 [77] 94 0.43 0.02∼10.26
Xiong shao capsule plus RWM versus RWM 1 [40] 108 0.62 0.30∼1.30
Overall (CHMs plus RWM versus RWM) 4 290 0.64 0.38∼1.08
Xiong shao capsule plus RWM versus R W Mp l u sp l a c e b o 2[ 67, 81] 426 0.48 0.30∼0.78
Overall (CHMs plus RWM versus RWM plus placebo) 2 426 0.48 0.30∼0.78
Repeat PCI
Dan hong tong mai capsule plus RWM versus RWM 1 [91] 138 0.39 0.08∼1.94
Dan shen plus RWM versus RWM 1 [52] 80 1.0 0.21∼4.66
Fu fang dan shen pill plus RWM versus RWM 2 [50, 57] 156 0.14 0.03∼0.58
Ku lie zi injection plus RWM versus RWM 1 [78] 40 0.33 0.01∼7.72
Lei gong teng plus RWM versus RWM 1 [43] 80 0.56 0.20∼1.51
Liang xue shen ji formula plus RWM versus RWM 1 [46] 97 0.54 0.14∼2.14
Si ni tang plus RWM versus RWM 1 [59] 80 0.56 0.20∼1.51
Tong xin luo plus RWM versus RWM 1 [90] 136 0.16 0.04∼0.68
Overall (CHMs plus RWM versus RWM) 9 807 0.37 0.23∼0.59
CABG
Dan hong tong mai capsule plus RWM versus RWM 1 [91] 138 0.14 0.01∼2.64
Dan shen plus RWM versus RWM 1 [52]8 0 N o t e s t i m a b l e
Fu fang dan shen pill plus RWM versus RWM 2 [50, 57] 156 0.32 0.03∼2.99
Liang xue sheng ji formula plus RWM versus RWM 1 [46] 97 0.30 0.01∼7.22
Tong xin luo plus RWM versus RWM 1 [90] 136 0.19 0.01∼3.86
Xiong shao capsule plus RWM versus RWM 1 [40] 108 1.04 0.07∼16.2
Overall (CHMs plus RWM versus RWM) 7 715 0.29 0.09∼0.96
Xiong shao capsule plus RWM versus R W Mp l u sp l a c e b o 2[ 67, 81] 426 0.20 0.02∼1.68
Overall (CHMs plus RWM versus RWM plus placebo) 2 426 0.20 0.02∼1.68
CABG = coronary artery bypass graft; CHM = Chinese herbal medicine; CI = conﬁdence interval; PCI = percutaneous coronary intervention; RWM = routine
Western medicine; MACE = major adverse cardiac event.
NG after 6 months’ followup was measured in 4 studies on
4C H M s( Table 7). Signiﬁcant diﬀerence was found between
the treatment group plus RWM and the control group with
thesameRWMaloneforGuantongformula(MD=0.21mm,
95%CI = 0.08 to 0.34mm) and Shu xue tong injection (MD
= 0.25mm, 95%CI = 0.09 to 0.41mm). The pooled results
of meta-analyses, suggested that CHMs plus RWM increased
net gain of lumen compared to using RWM alone (MD
= 0.2mm, 95%CI = 0.11 to 0.29mm). These results are
displayed in Table 7.
Lesion Area Net Gain (LANG) . Lesion area net gain is
deﬁned as the net increase in lumen area before PCI and
at followup after PCI [53, 55, 64, 82, 86]. Five studies onEvidence-Based Complementary and Alternative Medicine 13
Table 6: Risk ratios of Chinese herbal medicines administered to prevent angina after PCI.
Chinese herbal medicine Number of studies Number of patients Risk ratio (RR) 95% CI of RR
Followup 1 month
Shan shen tong mai he ji plus RWM versus RWM 1 [74] 102 1.18 0.95∼1.45
Shen mai gua lou shi xiao power plus RWM versus RWM 1 [88] 63 1.55 1.11∼2.17
Overall (CHMs plus RWM versus RWM)∗ 2 165 1.31 1.00∼1.72
Followup 3 months
Tong guan capsule plus RWM versus RWM 1 [58] 52 1.26 0.98∼1.64
Yi qu huo xue formula plus RWM versus RWM 1 [73] 101 1.07 0.98∼1.16
Overall (CHMs plus RWM versus RWM)∗ 2 153 1.13 0.93∼1.36
Followup 6 months
Xue fu zhu yu pill plus RWM versus RWM 1 [84] 84 1.02 0.57∼1.84
Wen yang huo xue formula plus RWM versus RWM 1 [47] 120 1.05 0.99∼1.12
Overall (CHMs plus RWM versus RWM) 2 204 1.05 0.99∼1.12
Total overall (CHMs plus RWM versus RWM)∗ 6 522 1.13 1.02∼1.26
∗Random eﬀect model
CHM = Chinese herbal medicine; CI = conﬁdence interval; PCI = percutaneous coronary intervention; RWM = routine Western medicine.
Table 7: Eﬀect of Chinese herbal medicines on angiographic characteristics after PCI.
Chinese herbal medicine Number of studies Number of patients Mean diﬀerence 95% CI of mean diﬀerence
Minimum lumen diameter (mm)
Fu fang dan shen plus RWM versus RWM 1 [86] 47 0.05 0.04∼0.26
Guan tong formula plus RWM versus RWM 1 [54] 120 0.21 0.06∼0.36
Lei gong teng plus RWM versus RWM 2 [43, 64] 119 0.11 −0.13∼0.36
Si ni tang plus RWM versus RWM 1 [59]6 30 . 2 6 −0.03∼0.55
Tong xin fang plus RWM versus RWM 1 [49]6 1 −0.10 −0.44∼0.24
Overall (CHMs plus RWM versus RWM) 6 410 0.15 0.05∼0.24
Xiong shao capsule plus RWM versus R W Mp l u sp l a c e b o 1[ 67] 97 0.49 0.12∼0.86
CHMs plus RWM versus RWM plus placebo 1 97 0.49 0.12∼0.86
Late loss of lumen (mm)
Fu fang dan shen plus RWM versus RWM 1 [86]4 70 . 0 0 −0.22∼0.22
Guan tong formula plus RWM versus RWM 1 [54] 120 −0.16 −0.28∼− 0.04
Lei gong ten plus RWM versus RWM 1 [64]5 3 −0.30 −0.48∼− 0.12
Shu xue tong injection plus RWM versus RWM 1 [56]6 4 −0.29 −0.44∼− 0.14
Tong xin luo plus RWM versus RWM 2 [55, 82] 148 −0.33 −0.46∼− 0.21
Overall (CHMs plus RWM versus RWM)∗ 6 432 −0.24 −0.34∼− 0.15
Net gain in lumen diameter (mm)
Fu fang dan shen plus RWM versus RWM 1 [86]4 70 . 0 4 −0.18∼0.26
Guan tong formula plus RWM versus RWM 1 [54] 120 0.21 0.08∼0.34
Lei gong tang plus RWM versus RWM 1 [64]5 30 . 2 8 −0.03∼0.59
Shu xue tong injection plus RWM versus RWM 1 [56] 64 0.25 0.09∼0.41
Overall (CHMs plus RWM versus RWM) 4 284 0.20 0.11∼0.29
Lesion area net gain (mm2)
Fu fang dan shen plus RWM versus RWM 1 [86]4 70 . 0 6 −0.54∼0.66
Guan tong formula plus RWM versus RWM 1 [54] 120 0.66 0.25∼1.07
Lei gong teng plus RWM versus RWM 1 [64] 53 0.66 0.41∼0.91
Tong xin luo plus RWM versus RWM 2 [55, 82] 148 0.99 0.64∼1.33
Overall (CHMs plus RWM versus RWM) 5 368 0.69 0.52∼0.87
∗Random eﬀect model
CHM = Chinese herbal medicine; CI = conﬁdence interval; PCI = percutaneous coronary intervention; RWM = routine Western medicine.14 Evidence-Based Complementary and Alternative Medicine
4 CHMs measured LANG at 6 months’ followup after PCI
(Table 7).The CHMs Guan tong formula, Tong xin luo, and
Lei gong teng demonstrated a signiﬁcant improvement in
LANG.ThesameresultwasnotfoundwiththefourthCHM,
Fu fang dan shen capsule. The pooled results of meta-analysis
were statistically signiﬁcant (MD = 0.69mm2, 95%CI = 0.52
to 0.87mm2).
3.4.8. Quality of Life. Two studies [45, 71] with randomized,
double-blind and placebo-control design reported quality of
life 1 month after PCI using the Chinese versions of the
SeattleAnginaQuestionnaire(SAQ)andShort-Form36(SF-
36) Health Survey. The SAQ is a 19-item self-administered
questionnaire that assesses how patients with CHD are
fairing in ﬁve dimensions: physical limitation (PL), angina
stability (AS), angina frequency (AF), treatment satisfaction
(TS), and disease perception (DP). The results of comparing
X u ef uz h uy uc a p s u l eplus RWM with the same RWM plus
placebo suggested that receiving CHM had a positive eﬀect
on AS (MD = 12.13,95%CI = 4.61 to 19.65) and TS (MD =
12.13, 95%CI = 6.19 to 17.87). However, in the study with
Tong guan capsule, the results were contrary to that of Xue
fu zhu yu capsule: AS (MD = −36.2, 95%CI = −48.97 to
−23.43), PL (MD = −11.32, 95%CI = −19.38 to −3.26),
AF (MD = −35.68, 95%CI = −50.16 to −20.6), TS (MD
= −25.03, 95%CI = −33.93 to −16.13), and DP (MD =
−9.79, 95%CI = −35.95 to −16.38). Pooled results were not
available because of heterogeneity and the I2(%) ranging
from 88% to 98%.
SF-36 is a survey of patient health comprised of eight
multiple-item scales measuring these dimensions: physical
function (PF), role-physical (RP), bodily pain (BP), general
health (GH), vitality (VT), social function (SF), role-
emotional (RE), and mental health (MH). There is also a
single-item measure that assesses health transition (HT).
Patients receiving Tong guan capsule had low scores on
all dimensions except for RP when compared to placebo
control. Patients administered Xue fu zhu yu capsule scored
high only on the RE dimension when compared to placebo
control.Wedidnotﬁndanystatisticallysigniﬁcantdiﬀerence
between the treatment and placebo groups in the remaining
dimensions. As with the SAQ, pooled results were not
available because of heterogeneity with I2(%) ranging from
85% to 98%.
4. Discussion
In this systematic review, 52 studies accounting for 4905
CAD patients whounderwent PCI were identiﬁed. Deﬁnitive
randomization was found in 19 studies and 33 studies were
found to be lacking deﬁnitive randomization. For the latter,
we attempted to contact authors by telephone or e-mail for
further information. But most replies were unsatisfactory
and did not resolve our questions; other authors did not
reply. Therefore, as a whole, the included studies were of low
quality. Of all studies, only four were designed to compare
CHMs plus RWM versus the same RWM plus placebo [45,
67, 71, 81]. The remaining studies were designed to compare
CHMs plus RWM versus the same RWM alone.
In the primary outcomes, 40 studies with 3805 patients
assessed in-stent restenosis after PCI. Twenty of these studies
involving 10 CHMs showed clear evidence of decrease in
restenosis rate. Furthermore, 13 of these studies were of low
ormoderateriskofbiasoveraminimum6months’followup
(Xiong shao capsule [67, 80, 81],D a ns h e n[44, 52, 85],G u a n
tong formula [54],B ux i ny i n[76], Jiang lian he ji [63] Shu
xin yin [75], Tong guan capsule [70], self-prepared guan tong
decoction [83], and X u ey ut o n gh ej i[69],). Therefore, a
moderate deﬁnitive conclusion can be drawn that CHMs are
beneﬁcial for preventing coronary restenosis after PCI. In
particular, the CHM Xiong shao capsule, which was studied
in 4 trials with 613 patients showed strong evidence with low
risk of bias in preventing restenosis [40, 67, 80, 81]. Other
CHMs including Dan shen [44, 50, 52, 85, 86]a n dTong
xin luo capsule [55, 79, 82, 90] showed the same signiﬁcant
result. But a deﬁnitive conclusion cannot be drawn because
of limited numbers of patients in these trials as well as their
low methodological quality.
We were unable to conclude whether CHMs decrease
cardiac mortality during 6 months’ followup after PCI.
Although the result of meta-analysis showed a statistically
signiﬁcant diﬀerence between comparison groups, we could
notassessasimilarresultintheanalysisofanysinglerelevant
trial.Thismaybeduetothelimited patientnumbersin these
studies.
Adverse events in the treatment groups were generally
higher than in controls for 5 CHMs, but a statistically
signiﬁcant diﬀerence was found in only one study on
the CHM Lei gong teng [43]. Adverse reactions in these
studies were reported as mild. Therefore, we feel further
investigation is needed to conﬁrm these reports.
In this review we also examined secondary outcomes,
measures of eﬀect post-PCI. Recurrent angina was followed
up for 6 months in 33 studies involving 22 CHMs. In 21
of these studies with 11 CHMs, patients in the treatment
group had signiﬁcantly lower incidence of recurrent angina
than those in the control group. Dan shen (capsule or pill)
in 5 studies [44, 50, 57, 85, 86], Xiong shao capsule in 4
studies [40, 67, 80, 81], Tong xin luo capsule in 3 studies
[79, 82, 90], and Tong mai yu xin concentrated pill in 2
studies [60, 62] were signiﬁcantly better than the control
at reducing recurrent angina after PCI. Minimum lumen
diameter in 7 studies with 6 CHMs, late loss of lumen in
6 studies with 5 CHMs, net gain in lumen diameter in 4
studies with 4 CHMs, and lesion area net gain in 5 studies
with 4 CHMs were measured, with results of meta-analyses
being statistically signiﬁcant. Studies on the following CHMs
revealed angiographic results in the treatment groups were
signiﬁcantly better than in the control group: Guan tong
formula [54] for minimum lumen diameter, late loss of
lumen, net gain in lumen diameter, and lesion area net gain;
Tong xin luo capsule [82] for late loss of lumen and area
net gain in lumen diameter; Shu xue tong [56] for late loss
of lumen and area net gain in lumen diameter; Xiong shao
capsule[67]forminimumlumendiameter;Leigongteng [64]
for late loss of lumenand lesion area net gain.
Our meta-analysis found possible beneﬁt in Chinese
herbal medicine compared to control in the rates ofEvidence-Based Complementary and Alternative Medicine 15
restenosis, cardiac mortality, recurrent angina, and in MLD,
NG, LLL, and LANG. Speciﬁcally, the CHMs Xiong shao
capsule and Dan shen appeared to markedly reduce rates
of restenosis and recurrent angina, and the CHM Tong xin
luo was found to signiﬁcantly reduce restenosis, recurrent
angina, LLL, and LANG. The baseline characteristics of
most studies, such as age, gender, severity of CAD, degree
of coronary stenosis before PCI, and stent type were not
signiﬁcantly diﬀerent between the treatment and control
groups. Nevertheless, concluding that CHMs have deﬁnitive
preventiveeﬀects on restenosis after PCI would be premature
because most of the studies were of low quality with
shortcomingssuchasinadequateconcealment,nonreporting
of dropouts, and their incomplete outcomes data point to
thepossibilityofbias.Additionally,clinicalheterogeneitywas
apparent because diﬀerent categories of CHMs were used.
The key limitations of our review were quality of the
included studies. Ideally, RCTs should adhere to known
research design standards. For example, the medication,
dosage, and course should be identical in the control
groups, and when including patients with diﬀerent levels
of illness, the trial should use stratiﬁed randomization.
Our examination of these studies did not ﬁnd enough
details of these characteristics though most of the included
studiesdidreportcomparablebaselinesbetweencomparison
groups. Details about randomization methodology were also
lacking. In the 52 studies we reviewed, 19 trials reported
randomization using a random number table or computer
random number generator such as SAS software, and 10
trials mentioned using sealed, opaque envelope concealment
without further explanation. In addition, in some studies
post-PCI angiographic assessment for restenosis was not
carried out in comparable patient numbers between the
studygroups.Forexample,theauthorsofonestudyreported
30 patients in the treatment group and 45 patients in the
control group. Post-PCI angiography was done on only 19
patients with 24 lesion vessels in the treatment group and on
26 patients with 29 lesion vessels in the control group, with 8
vesselsinthetreatmentgroupand13vesselsincontrolgroup
determinedtohaverestenosis[64].Noexplanationwasgiven
as to why angiographic assessment was not carried out on
comparable patient numbers. Thus this type of incomplete
outcome data can lead to selection bias.
Studies that involve therapeutic trials should also report
adverse events regardless of whether or not they occurred.
Reporting of adverse eﬀects is very important for evaluating
the safety of interventional measures even though there
is no certainty that the adverse event is related to the
interventional measure. Furthermore, adverse events can
aﬀe c ts t u d yd r o p o u tr a t e s .I no u rr e v i e w ,o n l y2 2o ft h e5 2
trials we investigated reported adverse events, rendering it
diﬃcult to systematically evaluate the safety of CHMs for
restenosis.
Most of the 52 studies did not mention type of stent
deployed, bare metal versus drug eluting. Therefore, the
level of eﬀectiveness of CHMs is unknown when diﬀerent
stent types are used. Future research on this topic will help
elucidate this.
Another area that did not receive attention in the studies
is the eﬀect of diabetes on restenosis. Persons with diabetes
who undergo PCI with stent placement have a high rate of
restenosis [94, 95]. Though diabetes was included in baseline
patient characteristics in the treatment and control groups
in most of the 52 studies of this review, none of the reports
indicated the impact diabetes may or may not have had on
restenosis. Furthermore, in China, CHMs are widely used
in the treatment of diabetes [26]. Researchers may want to
factor in these issues when designing future studies.
5. Conclusion andRecommendations
From this review, we conclude CHMs may have moderate
eﬃcacy in preventing restenosis following percutaneous
coronary intervention with stent placement. This is despite
the fact that our investigation revealed unclear method-
ological quality, clinical heterogeneity, and some possible
bias in the identiﬁed studies. Among the CHMs, Xiong
shao capsule appears to be somewhat eﬀective in preventing
restenosis because studies involving this CHM were of low
bias and had suﬃcient patient numbers. The CHM Dan
shen (capsule or pill) appears to have latent beneﬁcial eﬃcacy
in preventing restenosis because there were relatively more
studies and patient numbers for this CHM. Therefore, we
recommend that Dan shen should be a priority for further
research. We did not ﬁnd evidence of a beneﬁcial eﬀect for
administeringCHMstopreventmajoradversecardiaceﬀects
due to restenosis after PCI.
Future trials on CHMs as therapy to prevent restenosis
post-PCI need to adhere to established design standards
to overcome the limitations presented in this review. In
particular, they should ensure adequate concealment of
allocation and blinding of primary outcomes assessors.
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